Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Genes, bcl-2
  • Neoplasms
  • Oligonucleotides, Antisense
  • Thionucleotides

abstract

  • BCL-2 antisense therapy is well tolerated. Relative to other dose-finding studies of G3139, fatigue was somewhat more prominent in this study, possibly because of the protracted i.v. infusion schedule of the antisense oligonucleotide. Current randomized trials are using the highest daily dose established in this study given by shorter infusion periods (i.e., 7 mg/kg/day for 5-7 days) to enhance the antitumor activity of standard cytotoxic drugs.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11895895

Additional Document Info

start page

  • 679

end page

  • 83

volume

  • 8

number

  • 3